Ovarian

Initial PARP Inhibitor Use for Ovarian Cancer May Not Lead to Resistance in Secondary Use

(Curetoday.com) Mar 18, 2019 - Prior exposure to PARP inhibitor treatment may not lead to resistance in future use with these agents in women with recurrent epithelial ovarian cancer, meaning repeat use could become more common.

read article

Individualized Dosing Regimen Reduces Side Effects in Ovarian Cancer Maintenance Therapy

(Curetoday.com) Mar 18, 2019 - Side effects decreased among patients with high-risk ovarian cancer who received an individualized starting dose of Zejula (niraparib), based upon baseline bodyweight and platelet counts, compared with a fixed starting dose.

read article

Clovis Oncology To Highlight Rubraca® (Rucaparib) Data From Post-Hoc ARIEL3 Analyses At SGO 2019 Congress

(Clovis Oncology) Mar 16, 2019 - Exploratory analyses of ARIEL3 Rubraca data in recurrent ovarian cancer presented in oral plenary and poster sessions. Maintenance treatment with Rubraca improved median progression-free survival (PFS) and reduced the risk of progression vs placebo regardless of age subgroup.

read corporate press release

PARP Inhibitor Benefit Gets a TWiST in Recurrent Ovarian Ca

(MedPage Today) Mar 17, 2019 - In delaying disease progression in recurrent ovarian cancer, maintenance therapy with the PARP inhibitor niraparib (Zejula) also increased patients' time without symptoms or toxicity (TWiST), an analysis of the phase III NOVA trial found.

read article (free registration required)

Sutro Biopharma Initiates Phase I Clinical Trial of STRO-002 for the Treatment of Ovarian and Endometrial Cancers

(MarketWatch) Mar 15, 2019 - Sutro Biopharma, Inc. today announced that it has dosed the first patient in a Phase I study of STRO-002, an anti-folate receptor alpha (FoIRα) antibody-drug conjugate (ADC), in patients with ovarian and endometrial cancers.

read article

Persistent Long-term Fatigue Among Epithelial Ovarian Cancer Survivors

(ESMO) Mar 13, 2019 - A study among epithelial ovarian cancer survivors from 25 cooperative GINECO centres in France showed similar quality-of-life (QoL) compared to healthy controls that were randomly selected from the electoral rolls, but persistent long-term fatigue.

read article

Celsion Announces GEN-1 Data Presentation at ASCO-SITC Clinical Immuno-Oncology Symposium

(Yahoo! Finance) Mar 4, 2019 - Celsion Corporation, an oncology drug development company, today announced the oral presentation of data highlighting the safety, clinical response and translational data from its recently completed OVATION I Study.

read article

ImmunoGen Announces Top-Line Results from Phase 3 FORWARD I Study of Mirvetuximab Soravtansine in Ovarian Cancer

(ImmunoGen) Mar 1, 2019 - Trial did not meet primary endpoint of progression-free survival. Efficacy signal seen in high folate receptor alpha patients; additional analyses to be conducted. Favorable tolerability profile confirmed. Combination regimens to be evaluated as an independent path forward to support registration in ovarian cancer. ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that its Phase 3 FORWARD I trial evaluating the safety and efficacy of mirvetuximab soravtansine compared to chemotherapy in patients with folate receptor alpha (FRα)-positive, platinum-resistant ovarian cancer did not meet its primary endpoint of progression-free survival (PFS) in either the entire study population or in the pre-specified subset of patients with high FRα expression.

read corporate press release

Shares of Waltham Drugmaker ImmunoGen Crater After Late-Stage Trial Fail

(Boston Business Journal) Mar 1, 2019 - The future of beleaguered biotech ImmunoGen Inc.'s lead drug candidate is uncertain after the company revealed Friday that the ovarian cancer treatment failed in a late stage trial. In a 366-person Phase 3 trial, ImmunoGen's ovarian cancer drug was linked to a higher initial response rate compared to chemotherapy, but failed to lead to a longer survival rate without the cancer spreading. The company's shares were down 50 percent as of 9:45 a.m., the lowest point its seen since early 2017. The stock price gave the company a market value of $347 million.

read article

The Jackson Laboratory Signs A Research Agreement To Identify New Cancer Therapeutic Targets

(The Jackson Laboratory) Feb 28, 2019 - The Jackson Laboratory (JAX) announced today that it has signed a research agreement for up to $4.2 million with Sanofi to identify new targets to treat triple-negative breast cancer and ovarian carcinoma.

read press release

Atara Biotherapeutics Announces Presentations Highlighting Next-Generation CAR T Platform and Mesothelin-Targeted CAR T Clinical Results at American Association of Cancer Research (AACR) Annual Meeting 2019

(Atara) Feb 27, 2019 - Atara Biotherapeutics, Inc. today announced presentations highlighting next-generation CAR T platform and mesothelin-targeted CAR T clinical safety and efficacy results from Memorial Sloan Kettering Cancer Center (MSK) at the AACR Annual Meeting 2019.

read corporate press release

'Meticulous' Trial Overturns an Ovarian Cancer Practice

(Medscape Medical News) Feb 27, 2019 - For decades in advanced ovarian cancer, 'debulking' surgery has included regional lymph node removal. A landmark trial indicates no benefit.

read article (free registration required)

U.S. Investigating Johnson & Johnson Over Baby Powder’s Safety

(New York Times) Feb 21, 2019 - The Justice Department and Securities and Exchange Commission are investigating Johnson & Johnson over concerns about possible asbestos contamination of its popular baby powder and other talc-based products, the company said Wednesday. In a securities filing, Johnson & Johnson said it was “cooperating with these government inquiries and will be producing documents in response” to subpoenas it had received. In a separate statement, the company said that “the inquiries are related to news reports” about the welter of lawsuits it faces from consumers who claim its talc products caused cancers.

read article

Johnson & Johnson Says It’s Been Subpoenaed By SEC, Justice Department

(MarketWatch/WSJ) Feb 20, 2019 - Johnson & Johnson said Wednesday it received subpoenas from the U.S. Justice Department and the Securities and Exchange Commission seeking documents related to the safety of its signature baby powder and other talc-containing products. A J&J spokesman said the inquiries were related to news reports in December about product-liability lawsuits against the company, which caused J&J’s stock price to fall sharply. J&J disclosed the subpoenas in an annual report filed Wednesday with the SEC. The company said it would cooperate with the government inquiries and continue to defend itself in the product-liability litigation.

read article

The Financial Toxicity of Illness

(New York Times/Living With Cancer) Feb 21, 2019 - While medicine transforms cancer into a chronic disease with which patients can live for an extended period of time, financial toxicity threatens to turn chronic, too.

read article

Five Prime Therapeutics Doses First Patient in Phase 1b Trial of FPA150

(AP) Feb 20, 2019 - Five Prime Therapeutics, Inc., a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today announced that it initiated patient dosing in the Phase 1b dose expansion portion of the Phase 1a/1b clinical trial of FPA150 (FPA150-001; NCT03514121), a first-in-class immuno-oncology antibody that targets B7-H4.

read article

Artificial Intelligence Can Predict Survival Of Ovarian Cancer Patients

(Imperial College London [UK]) Feb 15, 2019 - Researchers have created new machine learning software that can forecast the survival rates and response to treatments of patients with ovarian cancer.

read article

Ovarian Cysts Should Be ‘Watched’ Rather Than Removed

(Imperial College London [UK]) Feb 5, 2019 - Women may not need to undergo surgery for non-cancerous ovarian cysts, avoiding potential surgical complications. This is the finding of new research, by a team of international scientists from institutions including Imperial College London and KU Leuven, published in The Lancet Oncology. The two-year study followed 1919 women from 10 different countries, including the UK, Belgium, Sweden and Italy, who were diagnosed with non-cancerous ovarian cysts.

read article

ImmunoGen Reports Recent Progress and 2018 Operating Results

(ImmunoGen) Feb 8, 2019 - Top-line data from phase 3 FORWARD I mirvetuximab soravtansine study on track for first half of 2019. Encouraging clinical data from novel IGN pipeline highlighted in two oral presentations at ASH 2018.

read corporate press release

Drug Target Identified For Chemotherapy-Resistant Ovarian, Breast Cancer

(WUSTL) Feb 4, 2019 - Researchers may have found a path toward improving the effectiveness of chemotherapy in people with breast or ovarian cancer that is caused by BRCA defects.

read article
Next Page